$ ▁ 1 . 3 ▁billion , ▁for ▁gene ▁chip ▁techn ologies ) ▁and ▁M TI - Global St em ▁( amount ▁unknown , ▁for ▁cell ▁trans fection ▁and ▁ne uro bi ology ), ▁both ▁in ▁ 2 0 1 6 ; ▁F E I ▁Company ▁( US $ ▁ 4 . 2 ▁billion , ▁an ▁electron ▁mic ros cope ▁manufact urer ), ▁F ines se ▁Sol utions ▁( amount ▁unknown , ▁for ▁bi op roduction ▁control ▁systems ▁and ▁software ), ▁Core ▁In format ics ▁( amount ▁unknown , ▁for ▁cloud - based ▁scientific ▁data ▁management ), ▁and ▁Pat he on ▁( US $ ▁ 7 . 2 ▁billion , ▁for ▁its ▁contract ▁development ▁and ▁manufact uring ▁services ), ▁all ▁in ▁ 2 0 1 7 ; ▁B ect on , ▁Dick inson ' s ▁Advanced ▁Bi opro cess ing ▁business ▁in ▁ 2 0 1 8 ▁( amount ▁unknown , ▁for ▁further ▁bi opro cess ing ▁products ); ▁and ▁Br ammer ▁Bio ▁in ▁ 2 0 1 9 ▁( US $ ▁ 1 . 7 ▁billion , ▁for ▁gene ▁ther apy ▁manufact uring ▁capabilities ). ▁ ▁As ▁of ▁ 2 0 1 7 , ▁the ▁company ▁had ▁reven ues ▁of ▁$ 2 1 ▁billion ▁and ▁was ▁a ▁Fort une ▁ 5 0 0 ▁company . ▁As ▁of ▁ 2 0 1 8 , ▁the ▁company ▁employed ▁on ▁the ▁order ▁of ▁ 7 0 , 0 0 0 ▁workers , ▁and ▁was ▁reporting ▁$ US ▁ 2 4 ▁billion ▁in ▁annual ▁reven ues